<Suppliers Price>

LCKLSL hydrochloride

Names

[ CAS No. ]:
533902-29-3

[ Name ]:
LCKLSL hydrochloride

Biological Activity

[Description]:

LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1].

[Related Catalog]:

Research Areas >> Cardiovascular Disease
Signaling Pathways >> Others >> Others

[Target]

Annexin A2 (AnxA2)[1]


[In Vitro]

In human retinal microvascular endothelial cells (RMVECs), treatment with LCKLSL (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions[1].

[In Vivo]

Application of LCKLSL in two in vivo models (in chicken chorioallantoic membrane and murine Matrigel plug assays) of angiogenesis demonstrates suppression of the angiogenic responses. Treatment with the LCKLSL peptide significantly decreases the vascular length. At a dose of 5 μg/mL, the LCKLSL peptide significantly decreases the number of vascular branches, junctions and end-points[1].

[References]

[1]. Mallika Valapala, et al. A Competitive Hexapeptide Inhibitor of Annexin A2 Prevents Hypoxia-Induced Angiogenic Events. J Cell Sci. 2011 May 1;124(Pt 9):1453-64.

Chemical & Physical Properties

[ Molecular Formula ]:
C30H57N7O8S

[ Molecular Weight ]:
675.88

Related Compounds